101 results
8-K
EX-99.1
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 … European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. “We're encouraged by the clinical activity and safety profile observed
8-K
ARVN
Arvinas Inc
16 May 24
Regulation FD Disclosure
6:05am
(63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination … follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile
8-K
ARVN
Arvinas Inc
11 Apr 24
Entry into a Material Definitive Agreement
7:03am
for convenience or upon a safety or regulatory issue.
The foregoing summaries of the License Agreement and the Asset Agreement are not complete
8-K
EX-99.1
ap5g9oh4w4lw6ql7or
27 Feb 24
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
7:02am
8-K
EX-99.2
wavv 3nla9x0
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
jthfr9b9 lwe
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-99.1
tsc pjkyotj
6 Dec 23
Regulation FD Disclosure
7:01am
8-K
EX-10.1
s9kkw4
27 Nov 23
Arvinas Announces Oversubscribed $350 Million Private Placement
7:11am
S-3ASR
EX-1.2
wppbzoufh2n5wec01l7o
7 Nov 23
Automatic shelf registration
5:24pm
8-K
EX-99.1
0u50lu2dc t59136
7 Nov 23
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-99.2
ui2h ydub3q
23 Oct 23
Regulation FD Disclosure
8:30am
8-K
EX-99.1
j1jgj8
8 Aug 23
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:03am
8-K
EX-3.1
hntygnp
21 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:32pm
8-K
EX-99.1
9a9wj4z7
8 Jun 23
Regulation FD Disclosure
7:14am
8-K
5ipgpzn0
8 Jun 23
Regulation FD Disclosure
7:14am